StockData
ARS Pharmaceuticals, Inc. logo

ARS Pharmaceuticals, Inc. (SPRY) stock

SPRYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/30
$3.65+0.06 (+1.67%)

Close on Nov 17, 2026Market cap $362.98MP/E –Yield –

ARS Pharmaceuticals operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

ARS Pharmaceuticals's operating cash flow for the twelve months ending Jun 30, 2026 was -$196.41M. For fiscal 2025 it was -$170.87M, down 1361.2% from the year before. The highest annual figure on record is $13.55M in fiscal 2024.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$170.87M-1361.2%
FY2024Dec 31, 2024$13.55M–
FY2023Dec 31, 2023-$59.27M–
FY2022Dec 31, 2022-$40.08M–
FY2021Dec 31, 2021-$17.56M–
FY2020Dec 31, 2020-$31.20M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$60.93M–
Q1 FY2026Mar 31, 2026-$44.95M–
Q4 FY2025Dec 31, 2025-$43.49M-203.5%
Q3 FY2025Sep 30, 2025-$47.05M–
Q2 FY2025Jun 30, 2025-$39.59M–
Q1 FY2025Mar 31, 2025-$40.74M–
Q4 FY2024Dec 31, 2024$42.00M–
Q3 FY2024Sep 30, 2024-$14.47M–
Q2 FY2024Jun 30, 2024-$7.28M–
Q1 FY2024Mar 31, 2024-$6.71M–
Q4 FY2023Dec 31, 2023-$17.41M–
Q3 FY2023Sep 30, 2023-$12.76M–
Q2 FY2023Jun 30, 2023-$16.67M–
Q1 FY2023Mar 31, 2023-$12.43M–
Q4 FY2022Dec 31, 2022-$20.50M-173.5%
Q3 FY2022Sep 30, 2022-$5.68M–
Q2 FY2022Jun 30, 2022-$6.97M–
Q1 FY2022Mar 31, 2022-$6.93M–
Q4 FY2021Dec 31, 2021$27.89M–
Q3 FY2021Sep 30, 2021-$19.12M–
Q2 FY2021Jun 30, 2021-$14.14M–
Q1 FY2021Mar 31, 2021-$12.20M–
Q4 FY2020Dec 31, 2020-$11.10M–
Q3 FY2020Sep 30, 2020-$7.03M–
Q2 FY2020Jun 30, 2020-$5.44M–
Q1 FY2020Mar 31, 2020-$7.63M–

More ARS Pharmaceuticals figures

See a number that looks wrong?